Development of TP-252 for the maintenance of remission in pediatric ulcerative colitis patients
Ended Project Grant Awarded Last action
- Award ID
- R44DK116463
- Recipient
-
Thetis Pharmaceuticals LLC UEI QBDWD3M7YKM9
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,899,962
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Originally
- Place of performance
- Connecticut, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $498,366 | |
| Amendment | $1,196,452 | |
| Amendment | $0 | |
| Original award | $205,144 |
Show all 11
Quick answers
Who received award R44DK116463?
R44DK116463 was awarded to Thetis Pharmaceuticals LLC by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on June 1, 2018.
How much is award R44DK116463 worth?
$1,899,962 has been obligated on R44DK116463.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award